Nucala
This is real life

Real world studies now support the findings of randomised control trials which prove the efficacy of Nucala (mepolizumab) in adults with severe eosinophilic asthma.1,2

This is a fictional patient for illustrative purposes

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg subcutaneously (SC) once every 4 weeks in adults and adolescents 12 years and older. The licenced dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight.1

Nucala is the only anti-IL-5 to demonstrate long-term reduction in exacerbations and oral corticosteroid (OCS) dose for up to 4.8 years, supported by real-world evidence.2,3

The maximum exposure duration of mepolizumab in the phase 3 and open label extension studies was 4.8 years. A patient withdrawal range of 4 weeks to 4.8 years was observed in MENSA, SIRIUS, COSMOS and COSMEX.

REALITI-A real-world study in adults2

REALITI-A is an ongoing 24-month, international, prospective, single-arm, observational cohort study enrolling patients aged 18 years and over with severe asthma and recently prescribed mepolizumab 100mg SC once every 4 weeks at physician’s discretion.2

The data below is a 12 month interim analysis. The analysis may not reflect the results from the final dataset.

Results are descriptive

aRate of clinically significant exacerbations was reduced from 4.28 12 months prior to mepolizumab exposure (n=821) to 1.23 in the 12 months post-exposure (n=820); rate ratio 0.29 (95% CI:0.26, 0.32); p<0.001.2
bMedian maintenance OCS dose reduced from 10.0 mg/day at baseline (n=298) to 2.5 mg/day at 1 year (n=222). The primary endpoint of exacerbation reduction was met.2

COSMEX long term study3

Could your patients benefit from reducing their OCS dose?

COSMEX (4.8 year study) 88% reduction in OCS dose vs. baseline at 2.5 years. Results are descriptive. Study not powered for statistical significance.
The maximum exposure duration of mepolizumab in the phase 3 and open label extension studies was 4.8 years. A patient withdrawal range of 4 weeks to 4.8 years was observed in MENSA, SIRIUS, COSMOS and COSMEX
In total, 95 patients with ≥188 weeks of continuous reporting across MENSA, COSMOS and COSMEX with ≤12 weeks between the last dose in COSMOS and first dose in COSMEX are summarised (MENSA: placebo [n=24], Nucala [n=71]). The Nucala group in MENSA contains patients on both 100mg SC and 75mg IV doses (75mg IV dose is not an approved dose of Nucala). Analyses include clinically significant exacerbations from MENSA and all exacerbations from COSMOS and COSMEX.

Nucala: Mechanism of action

Nucala

Nucala: The power to choose at home or in clinic administration1

Nucala offers at-home administration that lets appropriate patients self-administer without the need to come into the clinic or hospital. Nucala is the only 4-weekly asthma biologic with a simple fixed dose.1

Identify and support patients with severe eosinophilic asthma

Footnotes:

IV: intravenous; OCS: oral corticosteroids; SC: subcutaneously

References:

  1. Nucala SmPC
  2. Pilette C, et al. ERS 2021. Poster#3539
  3. Khurana S et al. Clin Ther 2019; 41:2041-2056

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.

June 2022 | PM-GB-MPL-WCNT-200040 (V4.0)